Bexson Biomedical announced that the U.S. military intends to field-test its Akeso wearable ketamine delivery device. Akeso, a ruggedized version of Bexson Biomedical’s wearable infusion device, utilizes Sevalent technology. Sevalent, Bexson’s proprietary formulation platform can work with small molecules across a broad range of drug classes. It enables subcutaneous intravenous (IV) therapy delivery. Bexson management […]
Bexson Biomedical
Stevanato Group, Bexson expand partnership for wearable drug delivery device
Stevanato Group and Bexson Biomedical announced today that they agreed to expand their drug delivery collaboration. Under the agreement, Bexson has access to the use of a customized version of Stevanato’s SG EZ-be Pod wearable delivery system so it can develop new therapeutics for treating an array of mental health conditions, including treatment-resistant depression and […]
FDA gives Bexson pre-IND guidance for ketamine formulation delivered by wearable pump
Bexson Biomedical announced today that it received pre-investigational new drug guidance from the FDA for its ketamine compound therapy. Santa Barbara, California-based Bexson develops the patented BB106 formulation, a ketamine therapy delivered through a wearable, subcutaneous patch pump in development with Stevanato Group. According to a news release, having reached the milestone of pre-IND guidance, […]
Stevanato Group brings in upsized IPO worth $453.5M
Stevanato Group announced today that the underwriters of its recently completed initial public offering purchased more than 1 million additional shares. The option exercised by the underwriters saw the acquisition of an additional 1,018,280 ordinary Stevanato Group shares at $21 per share. Piombino Dese, Italy–based Stevanato Group’s IPO resulted in net proceeds of approximately $453.5 […]
Bexson Biomedical aims to extend its wearable drug delivery device to psychoactive drugs
Bexson Biomedical announced today that it launched an R&D initiative to develop subcutaneous formulations of psychoactive therapeutics. Santa Barbara, Calif.-based Bexson’s effort will apply its existing subcutaneous formulation technology to build several psychoactive drug scaffolds for treating mental health indications, including post-traumatic stress disorder (PTSD) and depression. Formulations developed through the R&D initiative are designed […]
Bexson Biomedical wins U.S. patent for ketamine formulation
Bexson Biomedical announced that the U.S. Patent and Trademark Office (USPTO) granted a patent for its BB106 ketamine therapy. Santa Barbara, Calif.-based Bexson’s patent describes pharmaceutical formulations and treatment methods for the ketamine therapy, which the company believes allows for safety, comfort and pharmacokinetics that improve the administration of ketamine through multiple avenues, including the […]
Wearable infusion device maker Bexson Biomedical appoints SVP of drug delivery
Bexson Biomedical announced today that it appointed Sheldon Moberg as its new senior vice president of drug delivery. Santa Barbara, Calif.–based Bexson said in a news release that Moberg will lead the development of its drug delivery technologies, starting with a wearable infusion device for its BB106 therapy developed in partnership with Stevanato Group. The […]
